Welcome to Our Medtech Talk Podcast Channel

Too often we define the Medtech sector by the number of dollars raised, IPOs helped or companies sold. But the focus neglects the very foundation of the sector - the People. Join the Medtech Talk Podcast each week to hear from entrepreneurs, investors and executives who spend their days developing the tools that make sick people well and health care more efficient.



Medtech M&A: McEvoy on Where Will AMO Fit into J&J and What the Deal Means for Eye Care

September 21, 2016

 

Ashley McEvoy, company group chairman, Johnson & Johnson Vision Care and Johnson & Johnson Diabetes Care Companies, says the new force could pursue M&A in future expansion. Hear the details of the deal.

 

Ashley McEvoy

Company Group Chairman

Johnson & Johnson Vision

Ashley McEvoy is Company Group Chairman for Johnson & Johnson Vision and Diabetes Care Companies, two medically directed, consumer-informed businesses within the company’s global medical device segment. The companies, best known for their market-leading ACUVUE® Brand Contact lenses and ONETOUCH® Diabetes Devices, post annual sales of nearly $5 billion and are fully-integrated operating companies encompassing strategy, innovation, prototyping, clinical trials, sales, marketing, manufacturing, distribution, and business development and, employ more than 8,000 associates around the world. Ashley’s varied career that spans more than 20 years at J&J has given her a combination of health care, medical device and brand building savvy that make her particularly suited to size up and respond to the challenges inherent in running these hybrid businesses. Ashley’s accomplishments have been recognized by numerous business and philanthropic organizations and she was named a “2012 Working Mother of the Year” by Working Mother Magazine.

Meet Our Host, Geoff Pardo

Geoff has been in medtech for over two decades in both operational and investment roles. He is passionate about the industry potential and sharing stories from the front lines of innovation.